| 6-months’ follow-up |  | 15-months’ follow-up | ||||
---|---|---|---|---|---|---|---|
CC (n = 272) | TAU (n = 53) | P | Effect size | CC (n = 272) | TAU (n = 53) | P | |
Primary outcome | |||||||
 BDI-II | 13.3 (12.0–14.6) | 19.2 (15.6–22.7) | 0.002 | 0.52 | 11.8 (10.5–13.1) | 14.7 (11.0–18.4) | 0.138 |
Secondary outcomes | |||||||
 BAI | 11.0 (10.1–11.9) | 14.5 (11.7–17.3) | 0.024 |  | 9.3 (8.3–10.2) | 11.6 (8.7–14.4) | 0.132 |
 SCL-90-Ra | 59.2 (53.5–65.0) | 84.6 (63.4–105.8) | 0.024 |  | 36.1 (30.1–42.2) | 40.6 (16.8–64.4) | 0.719 |
 GAF | 68.0 (66.3–69.6) | 65.2 (61.1–69.3) | 0.228 |  | 71.2 (69.3–73.0) | 66.3 (60.1–72.6) | 0.149 |
Explorative outcomes | |||||||
 The Diagnostic Apathia Scale | 3.4 (3.0–3.8) | 4.3 (3.5–5.2) | 0.062 |  | 3.1 (2.6–3.5) | 3.9 (3.0–4.9) | 0.095 |
 PSP | 68.7 (67.2–70.1) | 66.9 (62.9–70.8) | 0.397 |  | 71.3 (69.7–72.9) | 68.7 (63.2–74.2) | 0.383 |
 SDS | 9.5 (8.5–10.6) | 11.0 (8.5–13.6) | 0.291 |  | 6.7 (5.5–7.8) | 9.1 (5.0–13.2) | 0.266 |
 WHO-5 | 54.2 (50.7–57.8) | 46.7 (40.2–53.2) | 0.044 |  | 54.3 (50.7–58.0) | 52.6 (43.5–61.8) | 0.738 |
    Personal Controlb | 22.5 (21.9–23.2) | 20.5 (18.9–22.1) | 0.024 |  | 22.4 (21.8–23.1) | 21.3 (19.9–22.7) | 0.141 |
 Control/Manage Depressionc | 6.3 (6.0–6.6) | 5.3 (4.5–6.2) | 0.033 |  | 6.2 (5.8–6.6) | 5.9 (4.9–6.8) | 0.467 |
 Obtain Help from Community, Family, Friendsc | 6.5 (6.2–6.8) | 5.2 (4.3–6.1) | 0.010 |  | 6.3 (6.0–6.7) | 6.1 (5.3–7.0) | 0.697 |
 EQ-5D-3 L | 0.8 (0.8–0.8) | 0.7 (0.6–0.8) | 0.007 |  | 0.8 (0.8–0.9) | 0.8 (0.7–0.8) | 0.174 |
 PRISEd | 14.0 (12.2–15.9) | 17.4 (13.5–21.3) | 0.132 |  | 12.4 (10.5–14.4) | 16.0 (11.1–20.9) | 0.178 |
 Remission, % | 53.9 (47.1–60.7) | 39.3 (25.2 53.3) | 0.069 |  | 61.9 (55.2–68.5) | 53.5 (37.9–69.1) | 0.310 |
 INSPIRE-S | 74.1 (70.1–78.1) | 50.3 (37.9–62.7) | < 0.001 |  | – | – |  |
 INSPIRE-R | 84.7 (81.9–87.6) | 60.8 (50.9–70.6) | < 0.001 |  | – | – |  |
 CSQ-8 | 26.7 (26.0–27.3) | 21.6 (19.8–23.3) | < 0.001 |  | – | – |  |